Hernexeos is now approved for use in patients with HER2-positive NSCLC, bringing it into direct competition with ADC Enhertu.

AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.

Despite its potential, incorporating new treatments like T-DXd into a first-line setting faces several barriers, explains Michael Hassett, MD, MPH, chief quality officer at Dana-Farber Cancer ...

As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” drug prices to ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

Daichii Sankyo's CFO Koji Ogawa tells CNBC's Squawk Box Asia what the pharma company is doing to mitigate the effects of U.S. tariffs, including optimizing its supply chain and expanding its ...

A joint research team led by Professor Eijiro Miyako of the Japan Advanced Institute of Science and Technology (JAIST), in ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

In August 2025, Biocad conducted a study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination ...

Boehringer Ingelheim GmbH won approval in the U.S. for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company.